Differences in hospital- and ventilator-associated pneumonia due to Staphylococcus aureus (methicillin-susceptible and methicillin-resistant) between Europe and Latin America: A comparison of the EUVAP and LATINVAP study cohorts

Medicina Intensiva

Volumn 37, Issue 4, 2013, Pages 241-247

  Rello, J ^a   Molano, D ^b   Villabon, M ^b   Reina, R ^d   Rita Quispe, R ^e   Previgliano, I ^c   Afonso, E ^a   Restrepo, M I ^f  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b University Hospital of San José   (Colombia)

^c Critical Care Department   (Argentina)

^d HOSPITAL SAN MARTÍN   (Argentina)

^e HOSPITAL NACIONAL DOS DE MAYO   (Peru)

^f University of Texas Health Science Center   (United States)

Author keywords

Methicillin resistant Staphylococcus aureus; Pneumonia; Respiratory infections; Staphylococcus aureus; Ventilator associated pneumonia

Indexed keywords

ADULT; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL FEATURE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DEMOGRAPHY; EPIDEMIOLOGICAL DATA; EUROPE; HOSPITAL ASSOCIATED PNEUMONIA; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MORTALITY; NONHUMAN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OXYGENATION; PNEUMONIA; PROSPECTIVE STUDY; SOUTH AND CENTRAL AMERICA; STAPHYLOCOCCAL PNEUMONIA; TREATMENT DURATION; VENTILATOR ASSOCIATED PNEUMONIA;

COHORT STUDIES; CROSS INFECTION; EUROPE; HUMANS; INTENSIVE CARE UNITS; LATIN AMERICA; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; PNEUMONIA, STAPHYLOCOCCAL; PNEUMONIA, VENTILATOR-ASSOCIATED; PROSPECTIVE STUDIES;

EID: 84892446039     PISSN: 02105691     EISSN: 15786749     Source Type: Journal    
DOI: 10.1016/j.medin.2012.04.008     Document Type: Article

References (27)

1. Vincent J.L., Rello J., Marshall J., Silva E., Anzueto A., Martin C.D., et al. International study of the prevalence and outcomes of infections in intensive care units. JAMA 2009, 302:2323-2329. EPIC II Group of Investigators.
2. Rello J., Quintana E., Ausina U., Puzo C., Net A., Prats G. Risk factors for Staphylococcus aureus nosocomial pneumonia in critically ill patients. Am Rev Respir Dis 1990, 142:1320-1324.
3. Rello J., Torres A., Ricart M., Valles J., Gonzalez J., Artigas A., et al. Ventilator-associated pneumonia by Staphylococcus aureus. Comparison of methicillin-resistant and methicillin-sensitive episodes. Am J Respir Crit Care Med 1994, 150(Pt 1):1515-1519.
4. Rello J., Ollendorf D.A., Oster G., Vera-Llonch M., Bellm L., Redman R., et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002, 122:2215-2221. VAP Outcomes Scientific Advisory Group.
5. Shorr A.F., Tabak Y.P., Gupta V., Johannes R.S., Liu L.Z., Kollef M.H. Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia. Crit Care 2006, 10:97.
6. Wunderink R.G., Niederman M.S., Kollef M.H., et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012, 54:621-629.
7. Kunkel M., Chastre J.E., Kollef M., Niederman M., Shorr A., Wunderink R., et al. Linezolid vs vancomycin in the treatment of nosocomial pneumonia proven due to methicillin-resistant Staphylococcus aureus. 48th Annual meeting of the Infectious Disease Society of America 2010, (Abstract 5047).
8. Koulenti D., Lisboa T., Brun-Buisson C., et al. Spectrum of practice in the diagnosis of nosocomial pneumonia in patients requiring mechanical ventilation in European intensive care units. Crit Care Med 2009, 37:2360-2368. EU-VAP/CAP Study Group.
9. Rello J., Gallego M. Diagnostic testing for ventilator-associated pneumonia. Clin Chest Med 1999, 20:671-679.
10. Vidaur L., Planas K., Sierra R., et al. Ventilator-associated pneumonia: impact of organisms on clinical resolution and medical resources utilization. Chest 2008, 133:625-632.
11. Shorr A.F., Combes A., Kollef M.H., Chastre J. Methicillin-resistant Staphylococcus aureus prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy. Crit Care Med 2006, 34:700-706.
12. Sader H.S., Joner R.N., Gales A.C., Silva J.B., Pignatari A.C. SENTRY antimicrobial surveillance program report: Latin American and Brazilian results for 1997-2001 through 2001. Braz J Infect Dis 2004, 8:25-79. SENTRY Participants Groups (Latin America).
13. Martinez-Capolino C., Reyes K., Johnson L., Sullivan J., Samuel L., Digiovine B., et al. Impact of surveillance on meticillin-resistant Staphylococcus aureus transmission and hospital resource utilisation. J Hosp Infect 2010, 74:232-237.
14. Athanassa Z., Siempos I.I., Falagas M.E. Impact of methicillin resistance on mortality in Staphylococcus aureus VAP: a systematic review. Eur Respir J 2008, 31:625-632.
15. Siempos I.I., Vardakas K.Z., Kyriakopoulos C.E., Ntaidou T.K., Falagas M.E. Predictors of mortality in adult patients with ventilator-associated pneumonia: a meta-analysis. Shock 2010, 33:590-601.
16. Hanberger H., Walther S., Leone M., Barie P., Rello J., Lipman J., et al. Increased mortality associated with meticillin-resistant Staphylococcus aureus (MRSA) infection in the Intensive Care Unit: results from the EPIC II study. Int J Antimicrob Agents 2011, 38:331-335.
17. Moise P.A., Schentag J.J. Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infection. Int J Antimicrob Agents 2000, 16:S31-S34.
18. Chastre J., Wolff M., Fagon J.-Y., et al. Comparison of 8 vs. 15 days of antibiotic therapy for ventilator-associated pneumonia in adults, a randomized trial. JAMA 2003, 290:2588-2598.
19. Luna C.M., Boyeras I.D. Management of meticillin-resistant Staphylococcus aureus pneumonia. Curr Opin Infect Dis 2010, 23:178-184.
20. Pea F., Viale P. Should the currently recommended twice-daily dosing still be considered the most appropriate regimen for treating MRSA ventilator-associated pneumonia with vancomycin?. Clin Pharmacokinet 2008, 47:147-152.
21. Rello J., Ulldemolins M., Lisboa T., Koulenti D., Mañez R., Martin-Loeches I., et al. Determinants of prescriptions and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia. Eur Resp J 2011, 1332-1339. the EUVAP/CAP Study Group.
22. Kollef M.H., Rello J., Cammarata S.K., Croos-Dabrera R.V., Wunderink R.G. Clinical cure and survival in gram-positive ventilator-associated pneumonia retrospective analysis of two double-blind studies comparing Linezolid with Vancomycin. Int Care Med 2004, 30:388-394.
23. Wunderink R.G., Rello J., Cammarata S.K., Croos-Dabrera R.V., Kollef M.H. Linezolid vs vancomycin analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003, 124:1789-1797.
24. Shorr A.F., Haque N., Taneja C., Zervos M., Lamerato L., Kothari S., et al. Clinical and economic outcomes for patients with health care-associated Staphylococcus aureus pneumonia. J Clin Microbiol 2010, 48:3258-3262.
25. Rice L.B. Rapid diagnostics and appropriate antibiotic use. Clin Inf Dis 2011, 52(Suppl. 4):S310-S357.
26. Restrepo M.I., Mortensen E.M., Rello J., Brody J., Anzueto A. Late admission to the UCI in patients with community-acquired pneumonia is associated with higher mortality. Chest 2010, 137:552-557.
27. Schramm G.E., Johnson J.A., Doherty J.A., Micek S.T., Kollef M.H. Methicillin-resistant Staphylococcus aureus sterile-site infection: the importance of appropriate initial antimicrobial treatment. Crit Care Med 2006, 34:2069-2074.